Table 2.
Combined sample characteristics and rates of severe COVID-19 outcomes for individuals who received a booster dose, across England (N=9·7 million), Northern Ireland (N=24 000), Scotland (N=2·7 million), and Wales (N=1·4 million)
|
Both vaccines |
mRNA-1273 |
BNT162b2 |
||||
|---|---|---|---|---|---|---|
| Total vaccination n (%) | Severe COVID-19 outcome (n, rate per 1000 person-years) | Total vaccination n (%) | Severe COVID-19 outcome (n, rate per 1000 person-years) | Total vaccination n (%) | Severe COVID-19 outcome (n, rate per 1000 person-years) | |
| Sex | ||||||
| Male | 6 529 700 (47·2%) | 12 650 (7·9) | 1 719 700 (50·6%) | 1110 (2·8) | 4 810 000 (46·1%) | 11 540 (9·6) |
| Female | 7 306 690 (52·8%) | 13 450 (7·3) | 1 676 870 (49·4%) | 1250 (3·2) | 5 629 820 (53·9%) | 12 200 (8·4) |
| Age | ||||||
| 18–49 years | 5 652 310 (40·9%) | 4410 (3·5) | 1 792 720 (52·8%) | 750 (2·0) | 3 859 580 (37·0%) | 3650 (4·2) |
| 50–54 years | 1 353 300 (9·8%) | 1210 (3·6) | 408 140 (12·0%) | 180 (1·8) | 945 160 (9·1%) | 1030 (4·3) |
| 55–59 years | 1 423 540 (10·3%) | 1410 (3·9) | 419 250 (12·3%) | 200 (2·0) | 1 004 290 (9·6%) | 1210 (4·7) |
| 60–64 years | 1 277 210 (9·2%) | 1570 (4·6) | 340 090 (10·0%) | 210 (2·4) | 937 120 (9·0%) | 1370 (5·4) |
| 65–69 years | 1 107 600 (8·0%) | 1860 (6·1) | 199 730 (5·9%) | 220 (4·0) | 907 870 (8·7%) | 1640 (6·5) |
| 70–74 years | 1 110 210 (8·0%) | 2610 (8·4) | 114 140 (3·4%) | 190 (5·7) | 996 070 (9·5%) | 2420 (8·7) |
| 75–79 years | 834 560 (6·0%) | 3250 (13·8) | 61 810 (1·8%) | 200 (10·3) | 772 760 (7·4%) | 3050 (14·1) |
| ≥80 years | 1 077 660 (7·8%) | 9770 (32·3) | 60 680 (1·8%) | 410 (22·9) | 1 016 980 (9·7%) | 9360 (32·9) |
| Ethnicity* | ||||||
| White | 8 893 590 (80·4%) | 18 530 (8·6) | 2 154 680 (80·8%) | 1360 (2·8) | 6 738 910 (80·3%) | 17 170 (10·3) |
| Asian | 637 580 (5·8%) | 860 (5·7) | 144 790 (5·4%) | 80 (2·3) | 492 790 (5·9%) | 790 (6·7) |
| Black | 172 990 (1·6%) | 290 (7·1) | 34 010 (1·3%) | 30 (3·4) | 138 980 (1·7%) | 270 (8·0) |
| Mixed | 115 950 (1·0%) | 160 (6·0) | 28 460 (1·1%) | 20 (3·2) | 87 490 (1·0%) | 140 (6·9) |
| Other | 99 750 (0·9%) | 150 (6·6) | 26 500 (1·0%) | 20 (3·2) | 73 250 (0·9%) | 130 (7·7) |
| Unknown | 1 142 490 (10·3%) | 1820 (6·5) | 279 340 (10·5%) | 130 (1·9) | 863 150 (10·3%) | 1690 (7·9) |
| Socioeconomic deprivation status | ||||||
| 1 (most deprived) | 2 051 520 (14·8%) | 4670 (9·5) | 515 790 (15·2%) | 470 (4·1) | 1 535 730 (14·7%) | 4200 (11·1) |
| 2 | 2 519 160 (18·2%) | 5080 (8·2) | 634 650 (18·7%) | 520 (3·6) | 1 884 510 (18·1%) | 4560 (9·6) |
| 3 | 2 818 550 (20·4%) | 5260 (7·5) | 647 110 (19·1%) | 420 (2·8) | 2 171 430 (20·8%) | 4840 (8·8) |
| 4 | 3 063 000 (22·1%) | 5430 (7·0) | 707 360 (20·8%) | 470 (2·8) | 2 355 640 (22·6%) | 4960 (8·2) |
| 5 (least deprived) | 3 368 540 (24·3%) | 5640 (6·6) | 887 270 (26·1%) | 470 (2·2) | 2 481 280 (23·8%) | 5170 (8·0) |
| Unknown | 15 620 (0·1%) | 30 (7·7) | 4400 (0·1%) | 10 (7·8) | 11 220 (0·1%) | 20 (7·6) |
| BMI† | ||||||
| <18·5 | 309 610 (2·2%) | 840 (12·0) | 79 920 (2·4%) | 60 (3·2) | 229 690 (2·2%) | 790 (14·9) |
| 18·5–24·9 | 3 895 910 (28·2%) | 7460 (8·0) | 953 870 (28·1%) | 610 (2·9) | 2 942 040 (28·2%) | 6850 (9·5) |
| 25·0–29·9 | 5 347 220 (38·7%) | 8610 (6·8) | 1 307 860 (38·6%) | 740 (2·6) | 4 039 360 (38·8%) | 7870 (8·0) |
| 30·0–34·9 | 2 104 790 (15·2%) | 4180 (8·2) | 496 820 (14·7%) | 380 (3·5) | 1 607 970 (15·4%) | 3800 (9·5) |
| 35·0–39·9 | 831 480 (6·0%) | 1720 (8·7) | 202 160 (6·0%) | 140 (3·3) | 629 320 (6·0%) | 1570 (10·2) |
| ≥40·0 | 477 750 (3·5%) | 1070 (9·3) | 114 440 (3·4%) | 110 (4·4) | 363 310 (3·5%) | 960 (10·7) |
| Unknown | 845 540 (6·1%) | 1100 (5·6) | 233 960 (6·9%) | 90 (1·7) | 611 580 (5·9%) | 1010 (7·1) |
| Number of risk groups† | ||||||
| 0 | 6 996 930 (50·7%) | 3880 (2·4) | 1 992 940 (58·8%) | 580 (1·4) | 5 003 990 (48·0%) | 3300 (2·8) |
| 1 | 3 589 070 (26·0%) | 4720 (5·5) | 866 490 (25·6%) | 520 (2·7) | 2 722 580 (26·1%) | 4210 (6·3) |
| 2 | 1 651 780 (12·0%) | 4690 (11·3) | 320 740 (9·5%) | 370 (4·9) | 1 331 030 (12·8%) | 4330 (12·7) |
| 3 | 827 980 (6·0%) | 4040 (18·9) | 129 160 (3·8%) | 260 (8·1) | 698 820 (6·7%) | 3780 (20·7) |
| 4 | 406 010 (2·9%) | 2990 (28·1) | 49 910 (1·5%) | 170 (13·5) | 356 100 (3·4%) | 2820 (30·0) |
| ≥5 | 340 540 (2·5%) | 4640 (51·6) | 29 780 (0·9%) | 240 (33·6) | 310 760 (3·0%) | 4400 (53·2) |
| Number of risk groups by British National Formulary chapters‡ | ||||||
| 0 | 8690 (36·1%) | 90 (1·7) | 2820 (37·4%) | 20 (1·4) | 5870 (35·5%) | 70 (1·8) |
| 1 | 4390 (18·2%) | 80 (2·7) | 1440 (19·1%) | 20 (2·2) | 2950 (17·8%) | 60 (2·9) |
| 2 | 3440 (14·3%) | 150 (6·0) | 1140 (15·1%) | 20 (2·6) | 2300 (13·9%) | 130 (7·5) |
| 3 | 2680 (11·1%) | 160 (8·5) | 830 (11·0%) | 40 (7·0) | 1850 (11·2%) | 130 (9·0) |
| 4 | 1960 (8·1%) | 170 (12·4) | 560 (7·4%) | 30 (7·7) | 1400 (8·5%) | 140 (14·1) |
| 5 | 1340 (5·6%) | 180 (20·9) | 350 (4·7%) | 30 (14·3) | 990 (6·0%) | 150 (23·2) |
| ≥6 | 1590 (6·6%) | 280 (29·5) | 410 (5·4%) | 50 (23·6) | 1190 (7·2%) | 220 (31·4) |
| Urban-rural index | ||||||
| Urban | 10 519 740 (76·0%) | 20 590 (7·9) | 2 662 240 (78·4%) | 1840 (3·0) | 7 857 490 (75·3%) | 18 750 (9·4) |
| Rural | 3 301 040 (23·9%) | 5490 (6·5) | 729 930 (21·5%) | 520 (2·9) | 2 571 110 (24·6%) | 4970 (7·5) |
| Unknown | 15 620 (0·1%) | 30 (7·7) | 4400 (0·1%) | 10 (7·8) | 11 220 (0·1%) | 20 (7·6) |
| Interval between primary vaccine doses | ||||||
| 3–6 weeks | 737 470 (5·3%) | 1670 (9·3) | 92 600 (2·7%) | 50 (2·5) | 644 860 (6·2%) | 1620 (10·2) |
| 7–8 weeks | 2 744 850 (19·8%) | 2500 (4·2) | 816 770 (24·0%) | 340 (2·0) | 1 928 080 (18·5%) | 2170 (5·0) |
| 9–10 weeks | 4 824 110 (34·9%) | 9540 (7·3) | 1 128 170 (33·2%) | 810 (2·9) | 3 695 940 (35·4%) | 8730 (8·6) |
| 11–12 weeks | 5 147 600 (37·2%) | 11 080 (8·6) | 1 252 880 (36·9%) | 1000 (3·4) | 3 894 720 (37·3%) | 10 070 (10·2) |
| ≥13 weeks | 382 380 (2·8%) | 1160 (14·5) | 106 150 (3·1%) | 160 (7·7) | 276 230 (2·6%) | 1000 (16·8) |
| Number of previous RT-PCR tests | ||||||
| 0 | 11 642 910 (84·1%) | 22 410 (7·7) | 2 732 530 (80·4%) | 1800 (2·8) | 8 910 380 (85·3%) | 20 610 (9·1) |
| 1 | 1 046 660 (7·6%) | 1110 (4·6) | 340 690 (10·0%) | 190 (2·8) | 705 970 (6·8%) | 920 (5·4) |
| 2 | 637 420 (4·6%) | 770 (5·1) | 193 230 (5·7%) | 130 (3·1) | 444 190 (4·3%) | 640 (5·9) |
| 3–4 | 290 460 (2·1%) | 710 (10·6) | 86 710 (2·6%) | 110 (6·3) | 203 750 (2·0%) | 610 (12·0) |
| 5–9 | 102 110 (0·7%) | 510 (18·9) | 25 110 (0·7%) | 80 (16·1) | 77 000 (0·7%) | 430 (19·5) |
| ≥10 | 116 830 (0·8%) | 410 (12·6) | 18 300 (0·5%) | 40 (11·5) | 98 530 (0·9%) | 370 (12·7) |
| Previous history of SARS-CoV-2 infection | ||||||
| No prior infection | 13 474 880 (97·4%) | 25 820 (7·7) | 3 280 550 (96·6%) | 2320 (3·0) | 10 194 330 (97·6%) | 23 500 (9·0) |
| <3 months | 122 150 (0·9%) | 110 (4·3) | 34 710 (1·0%) | 20 (3·0) | 87 440 (0·8%) | 90 (4·8) |
| 3–5 months | 100 480 (0·7%) | 120 (4·7) | 31 760 (0·9%) | 20 (2·7) | 68 720 (0·7%) | 100 (5·5) |
| 6–8 months | 80 580 (0·6%) | 60 (3·6) | 33 080 (1·0%) | 20 (2·8) | 47 500 (0·5%) | 40 (4·1) |
| ≥9 months | 58 310 (0·4%) | 50 (4·1) | 16 470 (0·5%) | 10 (4·5) | 41 840 (0·4%) | 40 (4·0) |
Rates are per 1000 person-years.
*
England and Wales.
†
England, Scotland, and Wales.
‡
Northern Ireland only.